CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Times cited: 21
- JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer discovery. 2015 Academic Article GET IT
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
The Journal of experimental medicine.
Times cited: 80